Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbapenem-sparing antibiotics versus meropenem for severe ESBL Enterobacteriaceae infection in ICU
2022-002636-31Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2022
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in extended-spectrum beta-lactamase-producing Enterobacterales infection comparing Piperacillin-tazobactam, Temocillin and Meropenem (3 arms). Primary endpoint: 30-day mortality. Started Aug 2022; status: active.
02
Drugs
piperacillin + tazobactamtemocillinmeropenem
03
Conditions
extended-spectrum beta-lactamase-producing Enterobacterales infection
Beyond the preview
Go deeper on 2022-002636-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002636-31.